- The pharmacology of multiple regimens of agalsidase alfa enzyme replacement therapy for Fabry disease2007 | 3. lékařská fakulta
- Safety and efficacy of pegunigalsidase alfa in patients with Fabry disease who were previously treated with agalsidase alfa: results from BRIDGE, a phase 3 open-label study2023 | 1. lékařská fakulta
- Fabry disease: overall effects of agalsidase alfa treatment2004 | 1. lékařská fakulta
- Effects of Baseline Left Ventricular Hypertrophy and Decreased Renal Function on Cardiovascular and Renal Outcomes in Patients with Fabry Disease Treated with Agalsidase Alfa: A Fabry Outcome Survey Study2020 | Publikace bez příslušnosti k fakultě
- Enzymatická substituční léčba agalsidázou alfa u nemocných s Fabryho chorobou: analýza dat z registru2009 | 1. lékařská fakulta
- Renoprotective Effect of Agalsidase Alfa: A Long-Term Follow-Up of Patients with Fabry Disease2022 | 1. lékařská fakulta
- Evaluation of the efficacy and safety of three dosing regimens of agalsidase alfa enzyme replacement therapy was underpowered - Authors' reply2015 | 1. lékařská fakulta
- Efekt enzymatické substituce agalsidázou alfa u Fabryho chorobou způsobené hypertrofické kardiomyopatie: 12 až 36 měsíční retrospektivní zaslepená echokardiografická analýza2009 | 1. lékařská fakulta
- Improved renal function under agalsidase alfa treatment in Fabry patientsPublikace bez příslušnosti k fakultě
- Improved renal function under agalsidase alfa treatment in Fabry patients (1)Publikace bez příslušnosti k fakultě
- Prompt Agalsidase Alfa Therapy Initiation is Associated with Improved Renal and Cardiovascular Outcomes in a Fabry Outcome Survey Analysis2021 | 1. lékařská fakulta
- FOS - Fabry outcome survey - is a useful tool to document Fabry disease and effects of agalsidase alfaPublikace bez příslušnosti k fakultě
- FOS - the Fabry Outcome Survey - is a useful tool to document Fabry disease and effects of agalsidase alfaPublikace bez příslušnosti k fakultě
- Positive European experience with agalsidase alfa in Fabry disease: update from FOS - the Fabry Outcome Survey +1Publikace bez příslušnosti k fakultě
- Safety of agalsidase alfa enzyme replacement therapy in a cohort of 1329 patients in FOS - The Fabry Outcome SurveyPublikace bez příslušnosti k fakultě
- Evaluation of the efficacy and safety of three dosing regimens of agalsidase alfa enzyme replacement therapy in adults with Fabry disease2015 | 1. lékařská fakulta
- Long-term follow-up in FOS - the Fabry Outcome Survey - confrims beneficial effects of agalsidase alfa on renal and other manifestations of Fabry diseasePublikace bez příslušnosti k fakultě
- Prevalence of neuropathic pain and stroke in patients with Fabry disease enrolled in FOS - Fabry Outcome Survey - before and after enzyme replacement therapy with agalsidase alfaPublikace bez příslušnosti k fakultě
- Effect of enzyme replacement therapy with agalsidase alfa on left ventricular mass in patients with Anderson Fabry disease: two-year results from FOS- the Fabry Outcome SurveyPublikace bez příslušnosti k fakultě
- Effect of enzyme replacement therapy with agalsidase alfa on left ventricular mass in patients with Anderson Fabry disease: two-year results from FOS - the Fabry Outcome SurveyPublikace bez příslušnosti k fakultě
- The effect of enzyme replacement therapy on clinical outcomes in male patients with Fabry disease: A systematic literature review by a European panel of experts2019 | 1. lékařská fakulta
- Léčba Fabryho choroby - agalsidáza alfa versus agalsidáza beta, mezinárodní studie : komentář2018 | 1. lékařská fakulta
- Fabry disease defined: baseline clinical manifestations of 366 patients in the Fabry Outcome Survey2004 | 1. lékařská fakulta
- Patients with Fabry Disease after Enzyme Replacement Therapy Dose Reduction Versus Treatment Switch2014 | Ústřední knihovna